An Fc-silenced humanized immunoglobulin G1 (IgG1) bispecific antibody targeting both the tumor-associated antigen (TAA) Claudin 6 (CLDN6; CLDN-6) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anti-CLDN6/CD3 bispecific antibody CTIM-76 targets and binds to both CLDN6 expressed on tumor cells and CD3 expressed on T-cells. This activates and redirects cytotoxic T-lymphocytes (CTLs) to CLDN6-expressing tumor cells, which leads to enhanced CTL-mediated killing of CLDN6-expressing tumor cells. CLDN6, a tight-junction protein and embryonic antigen, is overexpressed on a variety of tumor cells but is not or minimally expressed on normal, healthy adult cells.